Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients

Trial Profile

Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 13 Apr 2018 Planned initiation date changed from 15 May 2018 to 15 Aug 2018.
    • 19 Jan 2018 Planned End Date changed from 30 Jun 2019 to 31 Oct 2018.
    • 19 Jan 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top